| HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer | Capecitabine | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 2026-11-17 |
| Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5 | Capecitabine | Phase 3 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2026-11-17 |
| Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer | Fluorouracil | Phase 2 | Not yet recruiting | Damanhour University | 2026-11-17 |
| Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer | Pemetrexed | Phase 3 | Not yet recruiting | Goethe University | 2026-11-17 |
| RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma | Capecitabine, Fluorouracil | Phase 2 / Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 2026-11-13 |
| Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer | Pemetrexed | Phase 2 | Not yet recruiting | Guizhou Medical University | 2026-11-13 |
| SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3) | Capecitabine, Fluorouracil | Phase 3 | Not yet recruiting | Fudan University | 2026-11-12 |
| QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients | Fluorouracil | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2026-11-12 |
| Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Tegafur | Phase 2 | Recruiting | Beijing Tsinghua Chang Gung Hospital | 2026-11-12 |
| Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast Cancer | Capecitabine, Fluorouracil | — | Active, not recruiting | Peking Union Medical College Hospital | 2026-11-09 |
| GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis | Tegafur | Phase 1 | Not yet recruiting | Ruijin Hospital | 2026-11-06 |
| A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small Cell Lung Cancer | Pemetrexed | Phase 2 | Not yet recruiting | Tang-Du Hospital | 2026-11-05 |
| Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer | Capecitabine, Fluorouracil | Phase 3 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 2026-11-04 |
| Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer | Capecitabine, Fluorouracil | Phase 3 | Not yet recruiting | Zhai Wenlong | 2026-11-04 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer | Fluorouracil | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 2026-11-04 |
| Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial | Pemetrexed | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 2026-11-04 |
| Arginine-Restricted Diet Combined With Chemoradiotherapy in Neoadjuvant Rectal Cancer: A Phase Ib/II Trial | Capecitabine | Phase 1 / Phase 2 | Not yet recruiting | Xuelei Ma MD | 2026-11-03 |
| A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer | Pemetrexed | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 2026-10-27 |
| ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | Pemetrexed | Phase 3 | Not yet recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 2026-10-27 |
| Clinical and Radiographic Evaluation of Dia-Root Bio MTA for Indirect Pulp Capping in Young Permanent Molars | Pemetrexed | Not applicable | Recruiting | Tanta University | 2026-10-26 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer | Pemetrexed | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-10-26 |
| Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study | Tegafur | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2026-10-14 |
| Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer | Tegafur | Phase 2 | Recruiting | Ruijin Hospital | 2026-10-09 |
| Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma | Floxuridine | — | Recruiting | AdventHealth | 2026-09-29 |
| CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial | Floxuridine | Phase 1 | Not yet recruiting | City of Hope Medical Center | 2026-09-25 |
| A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma | Tegafur | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 2026-09-18 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma | Tegafur | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 2026-09-14 |
| A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression. | Tegafur | Phase 2 | Recruiting | Xijing Hospital | 2026-08-26 |
| Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcinoma | Tegafur | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 2026-08-19 |
| Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis | Floxuridine | Phase 2 | Recruiting | Sunnybrook Health Sciences Centre | 2026-08-14 |
| Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma | Raltitrexed | Early phase 1 | Active, not recruiting | Nanfang Hospital, Southern Medical University | 2026-08-05 |
| Effects of HIPEC on Postoperative Bowel Motility and Complications | Raltitrexed | — | Active, not recruiting | Peking University People's Hospital | 2026-01-20 |
| A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer | Raltitrexed | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2026-01-16 |
| QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT | Raltitrexed | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 2026-01-08 |
| Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy | Floxuridine | Phase 2 | Recruiting | Michael J Cavnar, MD | 2025-10-01 |
| Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery | Floxuridine | Phase 2 | Recruiting | Erasmus Medical Center | 2025-03-21 |
| Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy | Floxuridine | Phase 3 | Recruiting | The Netherlands Cancer Institute | 2025-03-04 |
| Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1,Chemotherapy and Target Therapy for Metastatic Colorectal Cancer | Raltitrexed | Phase 2 | Recruiting | Fudan University | 2025-02-24 |
| A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC | Raltitrexed | — | Not yet recruiting | Xuhua Duan | 2025-02-12 |
| HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence | Raltitrexed | Phase 2 | Recruiting | Fudan University | 2025-02-06 |
| CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC | Raltitrexed | Phase 2 | Not yet recruiting | Fudan University | 2024-10-30 |
| HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) | Floxuridine | Phase 2 | Recruiting | Oslo University Hospital | 2024-03-15 |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | Floxuridine | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 2023-05-17 |